Navigation Links
DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
Date:4/9/2013

San Diego, CA (PRWEB) April 09, 2013

The drug safety advocates at DrugRisks.com are alerting of updated legal news on the site for patients who have taken the diabetes drug Actos. Trial continues against the maker of the drug for a man alleging it caused his terminal bladder cancer***.

DrugRisks is designed to improve the safety of those taking popular prescription drugs like Actos by providing the latest warnings, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice.

The FDA and European Medicines Agency* have warned that taking Actos for longer than one year may be associated with an increased risk of bladder cancer. Regulators in France and Germany have also banned it from being prescribed**.

The resource center discovered as many as 3,000 patients in the U.S. have filed an Actos lawsuit against Takeda Pharmaceuticals over allegations their drug caused bladder cancer***. The first trial began last month in California for Jack Cooper, a grandfather who is terminally ill from the disease***.

Now DrugRisks notes an article from Law360 on March 26, 2013 which quotes the testimony in this case of Dr. Norm D. Smith, an assistant professor of urology and surgery at the University of Chicago, that Actos was the “most substantial causative factor” of Mr. Cooper’s advanced cancer****.

Lawyers continue to help those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.

Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*fda.gov/ForConsumers/ConsumerUpdates/ucm263431.htm#Actos; ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/hu an_pha_detail_000033.jsp&mid=WC0b01ac058001d126
**cbsnews.com/8301-504763_162-20070492-10391704.html
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html; Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court (Los Angeles).
****Claran McEvoy, "Actos 'Most Substantial" Factor in Man's Cancer, Doc Testifies," March 26, 2013, Law360

Read the full story at http://www.prweb.com/releases/actos-lawsuit-2013/bladder-cancer/prweb10610892.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
2. DrugRisks Stryker Recall Update: Company Warns Investors as Patients Alleging Injury Ask to Send Lawsuits to Federal Court
3. DrugRisks Center NuvaRing Lawsuit News: Drug Maker May Have Concealed Risks
4. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
5. DrugRisks Adds Update from First Actos Trial of Patient Alleging Bladder Cancer
6. Johnson & Johnson Ethicon Transvaginal Mesh Lawsuits Update: Resource4thePeople Reports Judge Schedules More Trials for This Summer
7. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
8. DrugRisk Update: Bayer Adds Gallbladder Claims to Yaz Settlements
9. Skechers Injury Lawsuit Update: Richard W. Schulte, Partner with Wright & Schulte LLC, Appointed to Plaintiffs’ Steering Committee in California Skechers Toning Shoes Litigation
10. DrugRisk Update: New Pradaxa Study Questions FDA Safety Conclusion
11. Hip Safety Center Update: Patients Ask to Send Stryker Hip Lawsuits to Federal Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... CO (PRWEB) , ... September 21, 2017 , ... ... Interview of the Month, Lewis and Clark College Emeritus Professor of Education Gregory ... Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... On ... Best Places to Work in the Research Triangle for 2017. , Winners were ... company had to meet a threshold in employee participation--a percentage that varies based ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror Mirror Beauty ... , Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the ... , Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting provider, holding ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group is proud ... The Guard®, has helped another long-time client pass their Department of Health and ... the law. , Thanks to the help of the Compliancy Group's Audit Response ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Five consumer ... innovation and market impact in 27 different categories. Nopavera Plus was named ... category will be announced at SupplySide West 2017 during presentations at SupplySide Central on ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, ... Pinnacle Professional Member in recognition of his contributions to ... serves as a Nephrologist at the practice of Kidney ... medicine, kidney care and hypertension solutions. He has worked ... years of career experience, as well as expertise in ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology: